Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Annexin A5 (Annexin V) is a cellular protein in the annexin group. Annexin V is a probe commonly used to detect apoptotic cells by its ability to bind to phosphatidylserine, a marker of apoptosis when it is on the outer leaflet of the plasma membrane.
IVISense Annexin-V 750 is a targeted fluorescent imaging agent comprising the selective protein, Annexin A5 and a near-infrared (NIR) fluorochrome. IVISense Annexin-V 750 enables in vivo visualization and quantification of the membrane-bound phospholipid, phosphotidylserine, exposed in the outer leaflet of the cell membrane lipid bilayer during the early stages of apoptosis.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IVISense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Atherosclerosis, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||750 nm|
Drug induced liver injury (DILI) is a major reason for late stage termination of drug discovery research projects, highlighting the importance of early integration of liver safety assessment in the drug development process. A technical approach for in vivo toxicology determination was developed using Acetaminophen (APAP), a commonly used over-the-counter analgesic and antipyretic drug, to induce acute hepatocellular liver injury.
Non-alcoholic fatty liver disease (NAFLD) describes a progressive pathology that affects the liver. Fat accumulation causes fatty liver (NAFL) or steatosis to develop, which leads to lipotoxicity and in turn induces liver inflammation and apoptosis, resulting in non-alcoholic steatohepatitis (NASH). NASH can progress to fibrosis and then cirrhosis, which in some cases will lead to hepatocellular carcinoma (HCC).
Read this case study to learn how non-invasive preclinical in vivo imaging was used to longitudinally visualize, quantify, and diagnose NASH with the goal of investigating the efficacy of liver fibrosis-preventing drugs on NAFLD progression.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best practices, from proper probe selection to study design to imaging technique tips and tricks needed to generate meaningful biological information from your in vivo fluorescence imaging studies.
Cancer chemotherapy can produce severe side effects such as suppression of immune function and damage to heart muscle, gastrointestinal tract, and liver. If serious enough, tissue injury can be a major reason for late stage termination of drug discovery research projects, so it is becoming more important to integrate safety/toxicology assessments earlier in the drug development process. There are a variety of traditional serum markers, tailored mechanistically to specific tissues, however there are no current non-invasive assessment tools that are capable of looking broadly at in situ biological changes in target and non-target tissue induced by chemical insult.
Protocol for Annexin-Vivo 750 In Vivo Fluorescent Imaging Agent
Annexin-Vivo™ 750 is a targeted fluorescence imaging agent comprising a selective protein, Annexin A5 and a near-infrared (NIR) fluorochrome. This agent has been developed to enable in vivo visualization and quantification of the membrane-bound phospholipid, phosphotidylserine, exposed in the outer leaflet of the cell membrane lipid bilayer during the early stages of apoptosis.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.